Hormone-Replacement Therapy and Its Association with Breast Cancer Subtypes: A Large Retrospective Cohort Study

Vered Rosenberg,1 Avital Bareket-Samish,2 Gabriel Chodick,1,3 Nava Siegelmann-Danieli3,4 1Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel; 2BioInsight Ltd, Binyamina, Israel; 3Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 4Department...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rosenberg V, Bareket-Samish A, Chodick G, Siegelmann-Danieli N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	breast cancer epidemiology hormone-replacement therapy incidence mammography Gynecology and obstetrics RG1-991
Acceso en línea:	https://doaj.org/article/b40d7920142f43bd82907f17e1983732
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b40d7920142f43bd82907f17e1983732
record_format	dspace
spelling	oai:doaj.org-article:b40d7920142f43bd82907f17e19837322021-12-02T19:17:36ZHormone-Replacement Therapy and Its Association with Breast Cancer Subtypes: A Large Retrospective Cohort Study1179-1411https://doaj.org/article/b40d7920142f43bd82907f17e19837322021-12-01T00:00:00Zhttps://www.dovepress.com/hormone-replacement-therapy-and-its-association-with-breast-cancer-sub-peer-reviewed-fulltext-article-IJWHhttps://doaj.org/toc/1179-1411Vered Rosenberg,1 Avital Bareket-Samish,2 Gabriel Chodick,1,3 Nava Siegelmann-Danieli3,4 1Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel; 2BioInsight Ltd, Binyamina, Israel; 3Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 4Department of Professional Medicine, Maccabi Healthcare Services, Tel Aviv, IsraelCorrespondence: Nava Siegelmann-Danieli Email danieli_na@mac.org.ilPurpose: The study examined trends in breast cancer incidence, mammography testing rates, hormone-replacement therapy (HRT) use and breast cancer subtypes in a large Israeli health maintenance organization during 2000– 2014.Methods: Annual rates of mammography tests and HRTs use were analyzed in women age ≥ 45. Annual incidence rates of breast cancer were analyzed in women age ≥ 20. Estimated annual percentage changes were used to test changes in incidence rates. Invasive breast cancer subtypes were approximated by treatments received. We compared annual rates and duration of HRTs use between women diagnosed with breast cancer and those who were not, as well as HRT use between subtypes of invasive breast cancer.Results: We identified 14,092 breast cancer cases (88% invasive, 12% in situ). The age-adjusted incidence rate of invasive breast cancer peaked in 2005, consistent with increased mammography screening that year, and decreased thereafter. HRT use decreased from 13.2% in 2002 to 4.6% in 2014. The subtypes distribution of 7771 patients diagnosed with invasive breast cancer during 2007– 2014 was: luminal A and B without HER2 over-expression (HR+/HER2-), 69.7%; Luminal B with HER2 over-expression (HR+/HER2+), 8.9%; Hormone receptor-negative HER2 enriched (HR-/HER2+), 5.4%; triple negative (HR-/HER2-), 10.0%; unknown, 6.0%. Overall, in women age ≥ 45 diagnosed with invasive breast cancer, 76– 86% did not have HRT exposure vs 14– 24% who were current (within 1 year before the breast cancer diagnosis), recent (within 2– 5 years), or past users (> 5 years). Current/recent HRT use was statistically significantly higher in luminal vs non-luminal/unknown breast cancer subtypes (13.9% vs 8.9%, respectively; p < 0.001).Conclusion: Our results show a decrease in breast cancer incidence that parallels the global and local decrease in HRT use. Yet, our results imply that current/recent HRT exposure may contribute to the incidence of luminal breast cancer tumors in particular. The magnitude of the effect supports findings from population-based studies.Keywords: breast cancer, epidemiology, hormone-replacement therapy, incidence, mammographyRosenberg VBareket-Samish AChodick GSiegelmann-Danieli NDove Medical Pressarticlebreast cancerepidemiologyhormone-replacement therapyincidencemammographyGynecology and obstetricsRG1-991ENInternational Journal of Women's Health, Vol Volume 13, Pp 1207-1216 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer epidemiology hormone-replacement therapy incidence mammography Gynecology and obstetrics RG1-991
spellingShingle	breast cancer epidemiology hormone-replacement therapy incidence mammography Gynecology and obstetrics RG1-991 Rosenberg V Bareket-Samish A Chodick G Siegelmann-Danieli N Hormone-Replacement Therapy and Its Association with Breast Cancer Subtypes: A Large Retrospective Cohort Study
description	Vered Rosenberg,1 Avital Bareket-Samish,2 Gabriel Chodick,1,3 Nava Siegelmann-Danieli3,4 1Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel; 2BioInsight Ltd, Binyamina, Israel; 3Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 4Department of Professional Medicine, Maccabi Healthcare Services, Tel Aviv, IsraelCorrespondence: Nava Siegelmann-Danieli Email danieli_na@mac.org.ilPurpose: The study examined trends in breast cancer incidence, mammography testing rates, hormone-replacement therapy (HRT) use and breast cancer subtypes in a large Israeli health maintenance organization during 2000– 2014.Methods: Annual rates of mammography tests and HRTs use were analyzed in women age ≥ 45. Annual incidence rates of breast cancer were analyzed in women age ≥ 20. Estimated annual percentage changes were used to test changes in incidence rates. Invasive breast cancer subtypes were approximated by treatments received. We compared annual rates and duration of HRTs use between women diagnosed with breast cancer and those who were not, as well as HRT use between subtypes of invasive breast cancer.Results: We identified 14,092 breast cancer cases (88% invasive, 12% in situ). The age-adjusted incidence rate of invasive breast cancer peaked in 2005, consistent with increased mammography screening that year, and decreased thereafter. HRT use decreased from 13.2% in 2002 to 4.6% in 2014. The subtypes distribution of 7771 patients diagnosed with invasive breast cancer during 2007– 2014 was: luminal A and B without HER2 over-expression (HR+/HER2-), 69.7%; Luminal B with HER2 over-expression (HR+/HER2+), 8.9%; Hormone receptor-negative HER2 enriched (HR-/HER2+), 5.4%; triple negative (HR-/HER2-), 10.0%; unknown, 6.0%. Overall, in women age ≥ 45 diagnosed with invasive breast cancer, 76– 86% did not have HRT exposure vs 14– 24% who were current (within 1 year before the breast cancer diagnosis), recent (within 2– 5 years), or past users (> 5 years). Current/recent HRT use was statistically significantly higher in luminal vs non-luminal/unknown breast cancer subtypes (13.9% vs 8.9%, respectively; p < 0.001).Conclusion: Our results show a decrease in breast cancer incidence that parallels the global and local decrease in HRT use. Yet, our results imply that current/recent HRT exposure may contribute to the incidence of luminal breast cancer tumors in particular. The magnitude of the effect supports findings from population-based studies.Keywords: breast cancer, epidemiology, hormone-replacement therapy, incidence, mammography
format	article
author	Rosenberg V Bareket-Samish A Chodick G Siegelmann-Danieli N
author_facet	Rosenberg V Bareket-Samish A Chodick G Siegelmann-Danieli N
author_sort	Rosenberg V
title	Hormone-Replacement Therapy and Its Association with Breast Cancer Subtypes: A Large Retrospective Cohort Study
title_short	Hormone-Replacement Therapy and Its Association with Breast Cancer Subtypes: A Large Retrospective Cohort Study
title_full	Hormone-Replacement Therapy and Its Association with Breast Cancer Subtypes: A Large Retrospective Cohort Study
title_fullStr	Hormone-Replacement Therapy and Its Association with Breast Cancer Subtypes: A Large Retrospective Cohort Study
title_full_unstemmed	Hormone-Replacement Therapy and Its Association with Breast Cancer Subtypes: A Large Retrospective Cohort Study
title_sort	hormone-replacement therapy and its association with breast cancer subtypes: a large retrospective cohort study
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/b40d7920142f43bd82907f17e1983732
work_keys_str_mv	AT rosenbergv hormonereplacementtherapyanditsassociationwithbreastcancersubtypesalargeretrospectivecohortstudy AT bareketsamisha hormonereplacementtherapyanditsassociationwithbreastcancersubtypesalargeretrospectivecohortstudy AT chodickg hormonereplacementtherapyanditsassociationwithbreastcancersubtypesalargeretrospectivecohortstudy AT siegelmanndanielin hormonereplacementtherapyanditsassociationwithbreastcancersubtypesalargeretrospectivecohortstudy
_version_	1718376873938911232

Hormone-Replacement Therapy and Its Association with Breast Cancer Subtypes: A Large Retrospective Cohort Study

Ejemplares similares